December 10, 2019

New Data from Ambry Genetics Showed Concurrent RNA and DNA Testing Identified More Patients with Hereditary Breast Cancer than DNA Testing Alone

Separate data demonstrated that finding mutations that increase risks for breast cancer frequently led clinicians to change their medical recommendations to patients. (Aliso Viejo, CA) December 10, 2019: Researchers at Ambry Genetics (Ambry), a leading clinical genetic testing lab, will announce ...

Read More

December 04, 2019

Caris Life Sciences and Ambry Genetics Partner to Advance Cancer Care

Partnership combines Caris’ somatic and Ambry’s germline testing strengths to provide clinicians with unique information about the molecular and genetic components of a patient’s cancer IRVING, Texas and ALISO VIEJO, Calif., December 4, 2019 – Caris Life Sciences®, a leading innovator ...

Read More

November 05, 2019

New Data from Ambry Genetics Show Substantial Increase in Diagnostic Yield, Further Supporting the Routine Use of RNA Genetic Testing for Hereditary Cancer Panels

Based on data from a prospective, nationwide, multi-center pilot, adding RNA genetic testing to DNA testing identified more disease-causing mutations compared to DNA-only testing. Results from a separate study demonstrated that genetic testing results frequently lead to changes in patient care ...

Read More

October 23, 2019

Ambry Genetics Published Data that Finds Adding RNA Genetic Testing Provides More Accurate, Actionable Results for Patients who Receive DNA Testing for Hereditary Cancer Risk

A new study published in JAMA Network Open demonstrates that RNA genetic testing can substantially improve the interpretation of DNA testing results and improve medical care (Aliso Viejo, CA) October 23, 2019: Ambry Genetics® (Ambry), a leading clinical genetics company, announced today the publication ...

Read More

October 15, 2019

New Data from Ambry Genetics Demonstrates Impact of First Major Advancement in Over 10 Years to Increase Diagnostic Yield in Genetic Testing for Hereditary Cancer Risk

In a prospective study, the addition of RNA genetic testing to hereditary cancer panels identified more disease-causing mutations in patients compared to DNA-only testing and clarified inconclusive results. Separate data showed RNA genetic testing’s ability to clarify the interpretation of complex ...

Read More

October 01, 2019

Ambry Genetics Makes Scientific Breakthrough and Launches Paired RNA and DNA Testing for Hereditary Cancer

+RNAinsight™ will help identify thousands more patients at increased risk for cancer (Aliso Viejo, CA) October 1, 2019: Ambry Genetics® (Ambry), a leading clinical genetic testing company, announced today the launch of +RNAinsight™, a major advancement in genetic testing. +RNAinsight enables ...

Read More

August 27, 2019

Ambry Genetics’ Data Reveal that Expanding Genetic Testing Guidelines Could Identify More Patients with Increased Risks of Cancer

Study finds that current guidelines exclude too many and test too narrowly, and reveals several new gene-cancer associations with potential to impact patient care. (Aliso Viejo, CA) August 27, 2019: Ambry Genetics (Ambry), a leading clinical genetics testing company, announced today new opportunities ...

Read More

July 16, 2019

hATTR CompassTM Genetic Testing Program Continues to Expand and Enable Diagnosis and Treatment of Hereditary ATTR Amyloidosis One Year Following Launch

Akcea and Ambry Genetics grow partnership, providing easily accessible, no-cost, confidential genetic testing and genetic counseling services to people with suspected hereditary ATTR amyloidosis Boston, Mass. and Aliso Viejo, Calif., July 16, 2019 (GLOBE NEWSWIRE) – Akcea Therapeutics, Inc. ...

Read More

June 06, 2019

Konica Minolta to Join Global Oncogenic Gene Panel Research

Move Strengthens Konica Minolta’s Advance into Personalized Medicine in Japan with Next-Generation Screening Capabilities TOKYO, Japan (June 6, 2019) - Konica Minolta, Inc. (Konica Minolta) today announces agreement with the University of Tokyo (UTokyo) and the National Cancer Center Japan ...

Read More

May 30, 2019

Research from Ambry Genetics & Mayo Clinic Reveals Differences in the Prevalence of Breast Cancer Genes among Racial and Ethnic Populations

Abstract to be presented at the 2019 American Society of Clinical Oncologists (ASCO) Annual Meeting (Aliso Viejo, CA) May 30, 2019: Researchers from Ambry Genetics (Ambry), a leading clinical genetics testing company, and Mayo Clinic, have documented significant differences in the prevalence of ...

Read More
Back 2 of 3 Next